ALID (Allied) EBIT per Share : $-0.07 (TTM As of May. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Allied EBIT per Share?

Allied's EBIT per Share for the three months ended in May. 2024 was $-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in May. 2024 was $-0.07.

During the past 3 years, the average EBIT per Share Growth Rate was -20.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Allied's EBIT per Share or its related term are showing as below:

ALID' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -20.1 Med: -20.1 Max: -20.1
Current: -20.1

During the past 6 years, the highest 3-Year average EBIT per Share Growth Rate of Allied was -20.10% per year. The lowest was -20.10% per year. And the median was -20.10% per year.

ALID's 3-Year EBIT Growth Rate is ranked worse than
83.73% of 836 companies
in the Drug Manufacturers industry
Industry Median: 6.8 vs ALID: -20.10

Allied's EBIT for the three months ended in May. 2024 was $-0.68 Mil.

Allied EBIT per Share Historical Data

The historical data trend for Allied's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allied EBIT per Share Chart

Allied Annual Data

Trend

Mar18

Mar19

Aug20

Aug21

Aug22

Aug23

EBIT per Share

Get a 7-Day Free Trial

-0.08

-0.13

-0.16

-0.10

Allied Quarterly Data
	Jun19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24
EBIT per Share	Get a 7-Day Free Trial															-0.02	-0.05	-0.01	-0.01	-0.01

Allied EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Allied's EBIT per Share for the fiscal year that ended in Aug. 2023 is calculated as

	EBIT per Share		(A: Aug. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-9.812	/	96.798
=	-0.10

Allied's EBIT per Share for the quarter that ended in May. 2024 is calculated as

	EBIT per Share		(Q: May. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.677	/	106.388
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in May. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.07

Allied (OTCPK:ALID) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Allied EBIT per Share Related Terms

Thank you for viewing the detailed overview of Allied's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Allied Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allied Corp (OTCPK:ALID) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1405 St. Paul Street, Suite 201, Kelowna, BC, CAN, V1Y 9N2

Website

https://www.allied.health

Allied Corp is an international cannabis company with a mission to help people suffering from Post-Traumatic Stress Disorder (PTSD) by researching, creating, and producing targeted cannabinoid health solutions. The company uses an evidence-informed scientific approach to make this mission possible through cutting-edge pharmaceutical research and development, plant-based production, and the development of therapeutic products. The company operates in two segments which include Allied and Allied Colombia. Its geographical segments consist of Colombia and Canada. The company's revenue is comprised ofsales ofcannabis products.

Executives

James George Robinson	director, 10 percent owner	10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Anthony Zelen	director, 10 percent owner	1406 MINE HILL LANE, KELOWNA A1 V1P 1S5
Calum Hughes	director, 10 percent owner, officer: Chief Executive Officer	1847 CROSSGLEN COURT, KELOWNA A1 V1V 1S4
David Weinkauf	director, 10 percent owner, officer: Chief Business Development Off	192 SIERRA MORENA LANDING, SW CALGARY A0 T3H 4K4
Paul James Bullock	director, 10 percent owner, officer: Chief Operating Officer	1400 ST PAUL ST, SUITE 201, KELOWNA Z4 V1Y9N2